Examination of point mutations within the ABL kinase domain of Bcr-Abl fusion gene in Chinese patients with chronic myeloid leukemia who develop imatinib resistance

被引：0
|
作者：
Yang, Dongguang [1 ]
Zhang, Ri [2 ]
Gang, Honglin [3 ]
Gu, Jian [2 ]
Cen, Jian Nong [2 ]
机构：
[1] Jiang Su Su Bei People Hosp, Yangzhou Inst Hematol, Jiangsu, Peoples R China
[2] Suzhou Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Suzhou 215006, Peoples R China
[3] Yangzhou Univ, Dept Pharmacol, Jiangsu, Peoples R China
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.4573.4573
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4573
引用
收藏
页码：214B / 215B
页数：2
相关论文
共 50 条
  • [41] Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib
    Press, Richard D.
    Willis, Stephanie G.
    Laudadio, Jennifer
    Mauro, Michael J.
    Deininger, Michael W. N.
    BLOOD, 2009, 114 (13) : 2598 - 2605
  • [42] HIGH RESOLUTION MELTING ANALYSIS FOR RAPID DETECTION OF BCR-ABL KINASE DOMAIN MUTATIONS IN CHRONIC MYELOGENOUS LEUKEMIA PATIENTS WITH IMATINIB RESISTANCE
    Andrikovics, H.
    Meggyesi, N.
    Bors, A.
    Halm, G.
    Nahajevszky, S.
    Lueff, S.
    Batai, A.
    Remenyi, P.
    Masszi, T.
    Tordai, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 490 - 490
  • [43] Serial but not single BCR-ABL transcript rises are predictive of ABL kinase mutations in chronic myeloid leukaemia patients treated by imatinib
    Wang, L
    Knight, K
    Lucas, CM
    Clark, RE
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 : 33 - 33
  • [44] BCR-ABL kinase domain mutations in patient with secondary but not primary resistance to imatinib.
    Al-Ali, HK
    Lange, T
    Krahl, R
    Mueller, C
    Patzer, G
    Niederwieser, D
    Deininger, MWN
    BLOOD, 2002, 100 (11) : 368A - 369A
  • [45] IMPACT OF BCR-ABL MUTATIONS ON RESPONSE TO DASATINIB IN ELDERLY CHRONIC MYELOID LEUKEMIA PATIENTS RESISTANT TO IMATINIB
    Tiribelli, M.
    Latagliata, R.
    Breccia, M.
    Luciano, L.
    Castagnetti, F.
    Gozzini, A.
    Cambrin, G. Rege
    Annunziata, M.
    Stagno, F.
    Pregno, P.
    Albano, F.
    Abruzzese, F.
    Musto, P.
    Sora, F.
    Ferrero, D.
    Montefusco, E.
    Cavazzini, F.
    Binotto, G.
    Fanin, R.
    Pane, F.
    Rosti, G.
    Santini, V.
    Fava, C.
    Alimena, G.
    Vigneri, P.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 347 - 347
  • [46] Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
    Jabbour, E.
    Kantarjian, H.
    Jones, D.
    Talpaz, M.
    Bekele, N.
    O'Brien, S.
    Zhou, X.
    Luthra, R.
    Garcia-Manero, G.
    Giles, F.
    Rios, M. B.
    Verstovsek, S.
    Cortes, J.
    LEUKEMIA, 2006, 20 (10) : 1767 - 1773
  • [47] Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
    E Jabbour
    H Kantarjian
    D Jones
    M Talpaz
    N Bekele
    S O'Brien
    X Zhou
    R Luthra
    G Garcia-Manero
    F Giles
    M B Rios
    S Verstovsek
    J Cortes
    Leukemia, 2006, 20 : 1767 - 1773
  • [48] Detection of BCR-ABL gene mutations in chronic myeloid leukemia using biochips
    A. Yu. Ikonnikova
    Yu. E. Yatsenko
    O. S. Kremenetskaya
    O. V. Vinogradova
    D. O. Fesenko
    I. S. Abramov
    V. A. Ovsepyan
    T. V. Nasedkina
    Molecular Biology, 2016, 50 : 412 - 416
  • [49] BCR-ABL independent gene mutations in children and adolescents with chronic myeloid leukemia
    Busch, M.
    Rinke, J.
    Schaefer, V
    Waldau, A.
    Ernst, J.
    Hochhaus, A.
    Gruhn, B.
    Ernst, T.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 53 - 54
  • [50] BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations?
    Gruber, Franz X.
    Lundan, Tuija
    Goll, Rasmus
    Silye, Aleksandra
    Mikkola, Ingvild
    Rekvig, Ole Petter
    Knuutila, Sakari
    Remes, Kari
    Gedde-Dahl, Tobias
    Porkka, Kimmo
    Hjorth-Hansen, Henrik
    MEDICAL ONCOLOGY, 2012, 29 (01) : 219 - 226
12345